Monopar Therapeutics is recovering a drug from the scrap heap of AstraZeneca’s rare disease pipeline. | Monopar Therapeutics ...

With new data out on Arcus Biosciences’ experimental HIF-2a inhibitor, one group of analysts figures the company could give ...

Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...

A new bombshell has been dropped in the scandal-plagued world of Alzheimer’s disease drug development. | Between the two ...

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...

Poseida Therapeutics’ gene therapy for hereditary angioedema (HAE) reduced kallikrein protein activity in a mouse model of ...

After receiving a green light earlier this year from the FDA, Medtronic has now collected a European approval for the latest ...

Lundbeck is slashing the book value of its $250 million Abide Therapeutics buyout in response to phase 1 data that triggered ...

Shortly after Bicara Therapeutics raised more than $360 million in an IPO, the cancer biotech and its former parent company ...

Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset ...

Massachusetts-based tech company Revvity has launched a new tool to remove a data entry chore from clinical laboratories. | ...

Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate ...